Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
62
TXG Quote, Financials, Valuation and Earnings
Last price:
$18.17
Seasonality move
:
1.77%
Day range:
$17.06 - $18.31
52-week range:
$6.78 - $20.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.44x
P/B ratio:
2.88x
Volume:
1.7M
Avg. volume:
3M
1-year change:
13.51%
Market cap:
$2.3B
Revenue:
$610.8M
EPS (TTM):
-$0.62
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TXG
10X Genomics, Inc.
|
$142.5M | -$0.07 | -5.46% | -85.12% | $16.57 |
|
AMS
American Shared Hospital Services
|
$7.5M | -- | -3.19% | -100% | $4.50 |
|
ASTH
Astrana Health, Inc.
|
$952.8M | $0.61 | 39.51% | 82.8% | $40.2500 |
|
CCEL
Cryo-Cell International, Inc.
|
$7.7M | -$0.09 | -4.04% | -60.92% | $8.50 |
|
OMCL
Omnicell, Inc.
|
$295.6M | $0.36 | 2.12% | 44.56% | $47.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TXG
10X Genomics, Inc.
|
$17.87 | $16.57 | $2.3B | -- | $0.00 | 0% | 3.44x |
|
AMS
American Shared Hospital Services
|
$2.07 | $4.50 | $13.5M | 11.73x | $0.00 | 0% | 0.46x |
|
ASTH
Astrana Health, Inc.
|
$22.7900 | $40.2500 | $1.1B | 119.95x | $0.00 | 0% | 0.39x |
|
CCEL
Cryo-Cell International, Inc.
|
$3.95 | $8.50 | $31.8M | 498.00x | $0.15 | 16.46% | 1.01x |
|
OMCL
Omnicell, Inc.
|
$39.61 | $47.33 | $1.8B | 92.89x | $0.00 | 0% | 1.57x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TXG
10X Genomics, Inc.
|
9.97% | 3.026 | 5.88% | 3.57x |
|
AMS
American Shared Hospital Services
|
50.05% | 0.126 | 110.57% | 1.02x |
|
ASTH
Astrana Health, Inc.
|
58.37% | -0.163 | 92.2% | 1.34x |
|
CCEL
Cryo-Cell International, Inc.
|
-564.01% | 1.723 | 33.28% | 0.78x |
|
OMCL
Omnicell, Inc.
|
14.48% | 0.834 | 15.13% | 1.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TXG
10X Genomics, Inc.
|
$100.9M | -$32.2M | -9.26% | -10.32% | -21.64% | $33.9M |
|
AMS
American Shared Hospital Services
|
$1.6M | $48K | -6.67% | -12.09% | 0.67% | -$2M |
|
ASTH
Astrana Health, Inc.
|
$81.6M | $19.2M | 0.88% | 1.85% | 2.01% | $7.4M |
|
CCEL
Cryo-Cell International, Inc.
|
$5.8M | $1.9M | -20.01% | -- | 24.29% | $2.5M |
|
OMCL
Omnicell, Inc.
|
$134.5M | $8.2M | 1.22% | 1.6% | 2.65% | $14M |
10X Genomics, Inc. vs. Competitors
-
Which has Higher Returns TXG or AMS?
American Shared Hospital Services has a net margin of -18.44% compared to 10X Genomics, Inc.'s net margin of -4.59%. 10X Genomics, Inc.'s return on equity of -10.32% beat American Shared Hospital Services's return on equity of -12.09%.
Company Gross Margin Earnings Per Share Invested Capital TXG10X Genomics, Inc.67.71% -$0.22 $872.1M AMSAmerican Shared Hospital Services21.94% -$0.00 $53.2M -
What do Analysts Say About TXG or AMS?
10X Genomics, Inc. has a consensus price target of $16.57, signalling downside risk potential of -7.27%. On the other hand American Shared Hospital Services has an analysts' consensus of $4.50 which suggests that it could grow by 117.39%. Given that American Shared Hospital Services has higher upside potential than 10X Genomics, Inc., analysts believe American Shared Hospital Services is more attractive than 10X Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TXG10X Genomics, Inc.5 11 0 AMSAmerican Shared Hospital Services0 0 0 -
Is TXG or AMS More Risky?
10X Genomics, Inc. has a beta of 2.148, which suggesting that the stock is 114.813% more volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.122, suggesting its less volatile than the S&P 500 by 87.793%.
-
Which is a Better Dividend Stock TXG or AMS?
10X Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10X Genomics, Inc. pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TXG or AMS?
10X Genomics, Inc. quarterly revenues are $149M, which are larger than American Shared Hospital Services quarterly revenues of $7.2M. 10X Genomics, Inc.'s net income of -$27.5M is lower than American Shared Hospital Services's net income of -$329K. Notably, 10X Genomics, Inc.'s price-to-earnings ratio is -- while American Shared Hospital Services's PE ratio is 11.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10X Genomics, Inc. is 3.44x versus 0.46x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TXG10X Genomics, Inc.3.44x -- $149M -$27.5M AMSAmerican Shared Hospital Services0.46x 11.73x $7.2M -$329K
-
Which has Higher Returns TXG or ASTH?
Astrana Health, Inc. has a net margin of -18.44% compared to 10X Genomics, Inc.'s net margin of 0.11%. 10X Genomics, Inc.'s return on equity of -10.32% beat Astrana Health, Inc.'s return on equity of 1.85%.
Company Gross Margin Earnings Per Share Invested Capital TXG10X Genomics, Inc.67.71% -$0.22 $872.1M ASTHAstrana Health, Inc.8.54% $0.01 $1.6B -
What do Analysts Say About TXG or ASTH?
10X Genomics, Inc. has a consensus price target of $16.57, signalling downside risk potential of -7.27%. On the other hand Astrana Health, Inc. has an analysts' consensus of $40.2500 which suggests that it could grow by 76.61%. Given that Astrana Health, Inc. has higher upside potential than 10X Genomics, Inc., analysts believe Astrana Health, Inc. is more attractive than 10X Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TXG10X Genomics, Inc.5 11 0 ASTHAstrana Health, Inc.8 2 0 -
Is TXG or ASTH More Risky?
10X Genomics, Inc. has a beta of 2.148, which suggesting that the stock is 114.813% more volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.862, suggesting its less volatile than the S&P 500 by 13.753%.
-
Which is a Better Dividend Stock TXG or ASTH?
10X Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10X Genomics, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TXG or ASTH?
10X Genomics, Inc. quarterly revenues are $149M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. 10X Genomics, Inc.'s net income of -$27.5M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, 10X Genomics, Inc.'s price-to-earnings ratio is -- while Astrana Health, Inc.'s PE ratio is 119.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10X Genomics, Inc. is 3.44x versus 0.39x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TXG10X Genomics, Inc.3.44x -- $149M -$27.5M ASTHAstrana Health, Inc.0.39x 119.95x $956M $1.1M
-
Which has Higher Returns TXG or CCEL?
Cryo-Cell International, Inc. has a net margin of -18.44% compared to 10X Genomics, Inc.'s net margin of 9.58%. 10X Genomics, Inc.'s return on equity of -10.32% beat Cryo-Cell International, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TXG10X Genomics, Inc.67.71% -$0.22 $872.1M CCELCryo-Cell International, Inc.74.61% $0.09 -$2.2M -
What do Analysts Say About TXG or CCEL?
10X Genomics, Inc. has a consensus price target of $16.57, signalling downside risk potential of -7.27%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 115.19%. Given that Cryo-Cell International, Inc. has higher upside potential than 10X Genomics, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than 10X Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TXG10X Genomics, Inc.5 11 0 CCELCryo-Cell International, Inc.0 1 0 -
Is TXG or CCEL More Risky?
10X Genomics, Inc. has a beta of 2.148, which suggesting that the stock is 114.813% more volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.089%.
-
Which is a Better Dividend Stock TXG or CCEL?
10X Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 16.46% to investors and pays a quarterly dividend of $0.15 per share. 10X Genomics, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.
-
Which has Better Financial Ratios TXG or CCEL?
10X Genomics, Inc. quarterly revenues are $149M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. 10X Genomics, Inc.'s net income of -$27.5M is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, 10X Genomics, Inc.'s price-to-earnings ratio is -- while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10X Genomics, Inc. is 3.44x versus 1.01x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TXG10X Genomics, Inc.3.44x -- $149M -$27.5M CCELCryo-Cell International, Inc.1.01x 498.00x $7.8M $749.4K
-
Which has Higher Returns TXG or OMCL?
Omnicell, Inc. has a net margin of -18.44% compared to 10X Genomics, Inc.'s net margin of 1.76%. 10X Genomics, Inc.'s return on equity of -10.32% beat Omnicell, Inc.'s return on equity of 1.6%.
Company Gross Margin Earnings Per Share Invested Capital TXG10X Genomics, Inc.67.71% -$0.22 $872.1M OMCLOmnicell, Inc.43.3% $0.12 $1.4B -
What do Analysts Say About TXG or OMCL?
10X Genomics, Inc. has a consensus price target of $16.57, signalling downside risk potential of -7.27%. On the other hand Omnicell, Inc. has an analysts' consensus of $47.33 which suggests that it could grow by 19.5%. Given that Omnicell, Inc. has higher upside potential than 10X Genomics, Inc., analysts believe Omnicell, Inc. is more attractive than 10X Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TXG10X Genomics, Inc.5 11 0 OMCLOmnicell, Inc.4 3 0 -
Is TXG or OMCL More Risky?
10X Genomics, Inc. has a beta of 2.148, which suggesting that the stock is 114.813% more volatile than S&P 500. In comparison Omnicell, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.868%.
-
Which is a Better Dividend Stock TXG or OMCL?
10X Genomics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 10X Genomics, Inc. pays -- of its earnings as a dividend. Omnicell, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TXG or OMCL?
10X Genomics, Inc. quarterly revenues are $149M, which are smaller than Omnicell, Inc. quarterly revenues of $310.6M. 10X Genomics, Inc.'s net income of -$27.5M is lower than Omnicell, Inc.'s net income of $5.5M. Notably, 10X Genomics, Inc.'s price-to-earnings ratio is -- while Omnicell, Inc.'s PE ratio is 92.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 10X Genomics, Inc. is 3.44x versus 1.57x for Omnicell, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TXG10X Genomics, Inc.3.44x -- $149M -$27.5M OMCLOmnicell, Inc.1.57x 92.89x $310.6M $5.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
